drugset
drugset / Trial / NCT03292250

Korean Cancer Study Group: Translational bIomarker Driven UMbrella Project for Head and Neck (TRIUMPH), Esophageal Squamous Cell Carcinoma- Part 1 (HNSCC)]

NCT03292250 ↗

Phase 2 Completed 180 enrolled Seoul National University Hospital Chungnam National University Hospital · collabKorean Cancer Study Group · collab
Non-randomizedParallel-groupOpen-labelPrevention

Summary

Open, multicenter, single arm, phase II, biomarker driven umbrella trial for head and neck squamous cell carcinoma

Timeline

Start
2017-09-10
Primary completion
2020-03-01
Completion
2022-03-10

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Abemaciclib Small molecule 200 mg Oral
Subject Alpelisib Small molecule 100 mg Oral
Subject Durvalumab Monoclonal antibody 750 mg Intravenous
Subject Nintedanib Small molecule 200 mg Oral
Subject Poziotinib Small molecule — Oral
Subject Tremelimumab Monoclonal antibody 75 mg Intravenous

Indications

head and neck squamous cell carcinoma